Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)
机构：[1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center.Pancreatic Cancer Institute, Fudan University.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai[2]Department of Gastroenterology,The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong中山大学附属第一医院[3]Department of Biliary-Pancreatic Surgery,Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong中山大学附属第二医院[4]Department of Gastroenterology, NanfangHospital, Southern Medical University, Guangzhou, Guangdong[5]Department of Medical Oncology, Shanghai Cancer Center,Fudan University, Shanghai[6]Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong Universityof Science and Technology, Wuhan, Hubei华中科技大学同济医学院附属同济医院[7]Department of Medical Oncology, Cancer Institute and Hospital, ChineseAcademy of Medical Sciences, Beijing[8]Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University,Guangzhou, Guangdong中山大学附属第一医院[9]Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai[10]Departmentof General Surgery, Guangdong General Hospital, Guangzhou, Guangdong广东省人民医院[11]Department of Pathology, Shanghai CancerCenter, Fudan University, Shanghai[12]Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou,Fujian[13]Department of General Surgery, Anhui Provincial Hospital, Hefei, Anhui[14]Department of GastrointestinalOncology, Peking University Cancer Hospital and Beijing Cancer Hospital, Beijing[15]Department of Radiology, PekingUniversity Cancer Hospital, Beijing[16]Department of Oncology, Southwest Hospital, Third Military Medical University,Chongqing[17]Department of Gastroenterology, Wuhan Union Hospital, Tongji Medical College, Huazhong University ofScience and Technology, Wuhan, Hubei华中科技大学同济医学院附属协和医院[18]Department of General Surgery, Changzheng Hospital, Second Military MedicalUniversity, Shanghai[19]Department of Gastroenterology, China-Japan Friendship Hospital, Beijing[20]Department ofHepatobiliopancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan四川大学华西医院[21]Department of Pathology,China-Japan Friendship Hospital, Beijing[22]Department of Hepatobiliopancreatic Surgery, The People's Hospital of Deyang,Chengdu, Sichuan[23]Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University,Chengdu, Sichuan四川大学华西医院[24]Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School ofMedicine, Shanghai[25]Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing[26]Departmentof Gastroenterology, Jiangsu People's Hospital, Nanjing, Jiangsu江苏省人民医院[27]Department of Gastroenterology, The SecondAffliated Hospital of Kunming Medical University, Yunnan Research Center for Liver Diseases, Kunming, Yunnan[28]Department of General Surgery, Peking University First Hospital, Beijing[29]Department of Surgery, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai[30]Department of Radiology, Shanghai Cancer Center, FudanUniversity, Shanghai[31]Department of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University Schoolof Medicine, Shanghai[32]Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University,Guangzhou, Guangdong中山大学附属第二医院[33]Department of Surgery, Huadong Hospital, Fudan University, Shanghai[34]Department of Gastricand Pancreatic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong[35]Department of InterventionalOncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou Guangdong中山大学附属第一医院[36]Department of HepatobiliarySurgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi[37]Department of Pathology, The FirstAffiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong中山大学附属第一医院[38]Department of Hepatobiliopancreatic Surgery,Huzhou Central Hospital, Huzhou, Zhejiang[39]Hepatobiliary Surgery Department V, Eastern Hepatobiliary Surgery Hospital,Shanghai[40]Department of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing[41]Department of Biliary-Pancreatic Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong中山大学附属第一医院[42]Department of General Surgery, Peking University Third Hospital, Beijing[43]Department of Oncology,Xiangya Hospital, Central South University, Changsha, Hunan[44]Department of Gastrointestinal and Pancreatic Surgery,Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, P.R. China
Pancreatic neuroendocrine neoplasms (p-NENs) are slowly growing tumors with frequent liver metastasis. There is a variety of approaches to treat non-functional p-NENs with synchronous liver metastasis (LM) which complicates the determination of optimal treatment. Based on updated literature review, we discussed the treatment strategy determinants for p-NEN with LM. According to the resectability of primary tumor, the WHO 2010 grade classification and the radiological type of liver metastasis, the CSNET group reached agreements on a number of issues, including the following. Prior to treatment, biopsy is required to confirm pathology. Liver biopsy is important for more accurate grading of tumor and percutaneous core needle biopsy is more available than EUS-FNA. In patients with unresectable primary, surgical resection for liver-metastatic lesions should be avoided. Curative surgery is recommended for G1/G2 p-NET with type I LM and R1 resection also seems to improve overall survival rate. Cytoreductive surgery is recommended for G1G2 p-NET with type II LM in select patients, and should meet stated requirements. Surgical resection for G1G2 p-NET with type III LM and p-NEC with LM should be avoided, and insufficient evidence exists to guide the surgical treatment of G3 p-NET with LM. Liver transplantation may be an option in highly select patients. In addition, the optimal time for surgical approach is still required for more evidence.
第一作者机构：[1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center.Pancreatic Cancer Institute, Fudan University.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center.Pancreatic Cancer Institute, Fudan University.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai[*1]Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, P.R. China
推荐引用方式(GB/T 7714)：
Kaizhou Jin,Jin Xu,Jie Chen,et al.Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)[J].INTERNATIONAL JOURNAL OF ONCOLOGY.2016,49(5):1991-2000.doi:10.3892/ijo.2016.3711.
APA：
Kaizhou Jin,Jin Xu,Jie Chen,Minhu Chen,Rufu Chen...&Xianjun Yu.(2016).Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET).INTERNATIONAL JOURNAL OF ONCOLOGY,49,(5)
MLA：
Kaizhou Jin,et al."Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)".INTERNATIONAL JOURNAL OF ONCOLOGY 49..5(2016):1991-2000
